Long-term prognostic value of growth differentiation factor-15 in acute coronary syndromes

被引:12
作者
Peiro, Oscar M. [1 ,2 ]
Garcia-Osuna, Alvaro [3 ,4 ]
Ordonez-Llanos, Jordi [3 ,4 ]
Cediel, German [5 ]
Bonet, Gil [1 ,2 ]
Rojas, Sergio [1 ,2 ]
Quintern, Veronica [1 ,2 ]
Bardaji, Alfredo [1 ,2 ]
机构
[1] Joan XXIII Univ Hosp, Dept Cardiol, Dr Mallafre Guasch 4, Tarragona 43007, Spain
[2] Rovira & Virgili Univ, Pere Virgili Hlth Res Inst, Tarragona, Spain
[3] Hosp Santa Creu & Sant Pau, Inst Biomed Res, Dept Clin Biochem, Barcelona, Spain
[4] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain
[5] Hosp Badalona Germans Trias & Pujol, Heart Inst, Badalona, Spain
关键词
MACROPHAGE INHIBITORY CYTOKINE-1; RISK STRATIFICATION; CARDIOVASCULAR EVENTS; INDEPENDENT MARKER; GLOBAL REGISTRY; HEART-FAILURE; MORTALITY; ASSOCIATION; RECEPTOR; DISEASE;
D O I
10.1016/j.clinbiochem.2019.07.014
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Growth Differentiation Factor-15 (GDF-15) predicts death and cardiovascular events in acute coronary syndromes (ACS). We aimed to assess the long-term prognostic value of GDF-15 in ACS. Methods: We included 358 patients with ACS who underwent coronary angiography. Plasma GDF-15 was measured and clinical data and long-term events were registered. Incremental value of GDF-15 for prognosing all-cause death above a clinical model including GRACE score, left ventricular ejection fraction < 40%, prior myocardial infarction and age was assessed. Results: GDF-15 concentrations > 1800 ng/L were associated with an increased prevalence of cardiovascular risk factors. During 6.5 years of follow-up 56 patients died, 7 had values of GDF-15 < 1200 ng/L, 7 between 1200 and 1800 ng/L and 42 > 1800 ng/L. After adjustment for potential confounders, GDF-15 > 1800 ng/L were independently associated with all-cause death (HR 4.09; 95% CI 1.57-10.71; p = .004) and the composite of major adverse cardiovascular events (MACE) (HR 2.48; 95% CI 1.41-4.34; p = .001). For long-term all-cause death a significant increase of ROC curve was seen after addition of GDF-15 to a clinical model 0.876 (95% CI 0.823-0.928; p = .014). Same improvements were found for net reclassification improvement (0.776; 95% CI 0.494-1.037; p < .001) and integrated discrimination improvement (0.112; 95% CI 0.055-0.169; p < .001). Multivariate competing risk model showed a significant association between GDF-15 > 1800 ng/L and the incidence of heart failure but not of myocardial infarction. Conclusions: In the setting of ACS, GDF-15 is associated with long-term all-cause death, MACE and heart failure and provides incremental prognostic value beyond traditional risks factor.
引用
收藏
页码:62 / 69
页数:8
相关论文
共 41 条
[1]  
[Anonymous], CIRCULATION CARDIOVA
[2]   Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome Observations From PROVE IT-TIMI 22 [J].
Bonaca, Marc P. ;
Morrow, David A. ;
Braunwald, Eugene ;
Cannon, Christopher P. ;
Jiang, Songtao ;
Breher, Stephanie ;
Sabatine, Marc S. ;
Kempf, Tibor ;
Wallentin, Lars ;
Wollert, Kai C. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (01) :203-210
[3]   MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily [J].
Bootcov, MR ;
Bauskin, AR ;
Valenzuela, SM ;
Moore, AG ;
Bansal, M ;
He, XY ;
Zhang, HP ;
Donnellan, M ;
Mahler, S ;
Pryor, K ;
Walsh, BJ ;
Nicholson, RC ;
Fairlie, WD ;
Por, SB ;
Robbins, JM ;
Breit, SN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (21) :11514-11519
[4]   Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial [J].
Bouabdallaoui, Nadia ;
Claggett, Brian ;
Zile, Michael R. ;
McMurray, John J. V. ;
O'Meara, Eileen ;
Packer, Milton ;
Prescott, Margarett F. ;
Swedberg, Karl ;
Solomon, Scott D. ;
Rouleau, Jean L. .
EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 (12) :1701-1709
[5]   Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study [J].
Brown, DA ;
Breit, SN ;
Buring, J ;
Fairlie, WD ;
Bauskin, AR ;
Liu, T ;
Ridker, PM .
LANCET, 2002, 359 (9324) :2159-2163
[6]   Long-term Cardiovascular Risk After Acute Coronary Syndrome, An Ongoing Challenge [J].
Bueno, Hector ;
Martin Asenjo, Roberto .
REVISTA ESPANOLA DE CARDIOLOGIA, 2016, 69 (01) :1-2
[7]   Growth-differentiation factor 15 for long-term prognostication in patients with non-ST-elevation acute coronary syndrome: An Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy [J].
Damman, Peter ;
Kempf, Tibor ;
Windhausen, Fons ;
van Straalen, Jan P. ;
Guba-Quint, Anja ;
Fischer, Johan ;
Tijssen, Jan G. P. ;
Wollert, Kai C. ;
de Winter, Robbert J. ;
Hirsch, Alexander .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 172 (02) :356-363
[8]   Growth-Differentiation Factor-15 Is a Robust, Independent Predictor of 11-Year Mortality Risk in Community-Dwelling Older Adults The Rancho Bernardo Study [J].
Daniels, Lori B. ;
Clopton, Paul ;
Laughlin, Gail A. ;
Maisel, Alan S. ;
Barrett-Connor, Elizabeth .
CIRCULATION, 2011, 123 (19) :2101-2110
[9]   Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis [J].
de Jager, Saskia C. A. ;
Bermudez, Beatriz ;
Bot, Ilze ;
Koenen, Rory R. ;
Bot, Martine ;
Kavelaars, Annemieke ;
de Waard, Vivian ;
Heijnen, Cobi J. ;
Muriana, Francisco J. G. ;
Weber, Christian ;
van Berkel, Theo J. C. ;
Kuiper, Johan ;
Lee, Se-Jin ;
Abia, Rocio ;
Biessen, Erik A. L. .
JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 208 (02) :217-225
[10]   Identification of Macrophage Inhibitory Cytokine-1 in Adipose Tissue and Its Secretion as an Adipokine by Human Adipocytes [J].
Ding, Qi ;
Mracek, Tomas ;
Gonzalez-Muniesa, Pedro ;
Kos, Katarina ;
Wilding, John ;
Trayhurn, Paul ;
Bing, Chen .
ENDOCRINOLOGY, 2009, 150 (04) :1688-1696